Patents Assigned to Hydra Biosciences, Inc.
  • Patent number: 10399982
    Abstract: Compounds, compositions and methods are described for inhibiting the TRPC5 ion channel and disorders related to TRPC5.
    Type: Grant
    Filed: May 2, 2018
    Date of Patent: September 3, 2019
    Assignee: Hydra Biosciences, Inc.
    Inventors: Bertrand L. Chenard, Randall J. Gallaschun
  • Patent number: 10329292
    Abstract: The present invention relates to substituted xanthine derivatives, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment of conditions having an association with TRPC5 containing ion channels.
    Type: Grant
    Filed: July 10, 2018
    Date of Patent: June 25, 2019
    Assignees: Boehringer Ingelheim International GmbH, Hydra Biosciences, Inc.
    Inventors: Kai Gerlach, Christian Eickmeier, Achim Sauer, Stefan Just, Bertrand L. Chenard
  • Patent number: 10221177
    Abstract: The present invention relates to pharmaceutical compounds of the Formula (I), or a pharmaceutically acceptable salt or composition thereof, and methods of their use for the treatment of pain, respiratory conditions, as well as inhibiting the Transient Receptor Potential A1 ion channel (TRPA1).
    Type: Grant
    Filed: September 18, 2015
    Date of Patent: March 5, 2019
    Assignee: Hydra Biosciences, Inc.
    Inventors: Bertrand L. Chenard, Xinyuan Wu
  • Patent number: 9980968
    Abstract: Compounds and compositions for treating injuries caused by exposure to chemical warfare agents are described herein.
    Type: Grant
    Filed: January 6, 2016
    Date of Patent: May 29, 2018
    Assignee: HYDRA BIOSCIENCES, INC.
    Inventor: Jayhong A. Chong
  • Patent number: 9969736
    Abstract: Compounds, compositions and methods are described for inhibiting the TRPC5 ion channel and disorders related to TRPC5.
    Type: Grant
    Filed: June 14, 2017
    Date of Patent: May 15, 2018
    Assignee: Hydra Biosciences, Inc.
    Inventors: Bertrand L. Chenard, Randall J. Gallaschun
  • Patent number: 9951073
    Abstract: Compounds and compositions for treating injuries caused by exposure to chemical warfare agents are described herein.
    Type: Grant
    Filed: October 26, 2012
    Date of Patent: April 24, 2018
    Assignee: Hydra Biosciences, Inc.
    Inventor: Jayhong A. Chong
  • Publication number: 20180093986
    Abstract: The present application relates to compounds and methods for treating pain, incontinence and other conditions.
    Type: Application
    Filed: October 13, 2017
    Publication date: April 5, 2018
    Applicants: Hydra Biosciences, Inc., Hydra Biosciences, Inc.
    Inventors: Magdalene M. Moran, Christopher Fanger, Jayhong A. Chong, Colleen McNamara, Xiaoguang Zhen, Josh Mandel-Brehm
  • Patent number: 9895356
    Abstract: Methods of treating a TRPC5 mediated disorder in a subject by administering an effective amount of a TRPC5 antagonist, such as a compound disclosed herein, are described.
    Type: Grant
    Filed: August 27, 2015
    Date of Patent: February 20, 2018
    Assignee: Hydra Biosciences, Inc.
    Inventors: Jayhong A. Chong, Christopher Fanger, Magdalene M. Moran, Elisha Singer, Timothy Strassmaier, Howard Ng
  • Patent number: 9815838
    Abstract: The present application relates to compounds and methods for treating pain, incontinence and other conditions.
    Type: Grant
    Filed: August 14, 2013
    Date of Patent: November 14, 2017
    Assignee: Hydra Biosciences, Inc.
    Inventors: Magdalene M. Moran, Christopher Fanger, Jayhong A. Chong, Colleen Mcnamara, Xiaoguang Zhen, Josh Mandel-Brehm
  • Patent number: 9745272
    Abstract: This invention relates to novel Quinazoline-2,4(1H,3H)-dione derivatives of Formula (I): and their use as TRPC5 modulators, pharmaceutical compositions containing the same, and methods of using the same as agents for the treatment of TRPC5 receptor mediated disorders or conditions. R1, R2, R3 and R4 have meanings given in the description.
    Type: Grant
    Filed: August 10, 2015
    Date of Patent: August 29, 2017
    Assignee: Hydra Biosciences, Inc.
    Inventors: Bertrand L. Chenard, Randall J. Gallaschun
  • Patent number: 9732050
    Abstract: The invention provides novel compositions and compounds that inhibit CatSper channel activity, that preferentially inhibits sperm hyperactivity over sperm motility, or both. The compounds of the invention are useful as contraceptive agents that may be adminstered to males, females, or concurrently to both sexual partners. The invention further provides methods of conducting drug discovery business and of conducting a reproductive medicine business. The invention also provides methods of identifying compounds that modulate sperm hypermotility.
    Type: Grant
    Filed: December 22, 2014
    Date of Patent: August 15, 2017
    Assignee: Hydra Biosciences, Inc.
    Inventors: Jayhong A. Chong, Magdalene M. Moran
  • Patent number: 9649315
    Abstract: Compounds and compositions for treating disorders related to TRPA1 are described herein.
    Type: Grant
    Filed: March 9, 2015
    Date of Patent: May 16, 2017
    Assignee: Hydra Biosciences, Inc.
    Inventors: Howard Ng, Jianfeng Hang
  • Patent number: 9505756
    Abstract: Compounds and compositions for treating disorders related to TRPA1 are described herein.
    Type: Grant
    Filed: February 6, 2015
    Date of Patent: November 29, 2016
    Assignee: HYDRA BIOSCIENCES, INC.
    Inventors: Xinyuan Wu, Spencer David Kimball, Ping Chen, Ding Zhou, Shaoping Peng
  • Patent number: 9486455
    Abstract: The present application relates to compounds and methods for treating pain and other conditions related to TRPV3.
    Type: Grant
    Filed: March 4, 2011
    Date of Patent: November 8, 2016
    Assignee: HYDRA BIOSCIENCES, INC.
    Inventors: Jayhong A. Chong, Christopher Fanger, Glenn R. Larsen, Magdalene M. Moran, Howard Ng, Amy Ripka, Dennis John Underwood, Manfred Weigele, Xiaoguang Zhen
  • Patent number: 9447114
    Abstract: This invention relates to novel Thieno- and Furo[2,3-d]pyrimidine-2,4[1H,3H]-dione derivatives of formula I and their use as TRPC5 modulators, pharmaceutical compositions containing the same, and methods of using the same as agents for the treatment of TRPC5 receptor mediated disorders or conditions. A, R1, R2, R3 and R4 have meanings given in the description.
    Type: Grant
    Filed: August 10, 2015
    Date of Patent: September 20, 2016
    Assignee: Hydra Biosciences, Inc.
    Inventors: Bertrand L. Chenard, Randall J. Gallaschun
  • Patent number: 9440973
    Abstract: This invention relates to novel Pyrido[3,4-d]pyrimidine-2,4(1H,3H)-dione derivatives of Formula (I): and their use as TRPC5 modulators, pharmaceutical compositions containing the same, and methods of using the same as agents for the treatment of TRPC5 receptor mediated disorders or conditions. R1, R2, R3 and R4 have meanings given in the description.
    Type: Grant
    Filed: August 10, 2015
    Date of Patent: September 13, 2016
    Assignee: Hydra Biosciences, Inc.
    Inventors: Bertrand L. Chenard, Randall J. Gallaschun
  • Patent number: 9440983
    Abstract: This invention relates to novel Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione derivatives of Formula (I): and their use as TRPC5 modulators, pharmaceutical compositions containing the same, and methods of using the same as agents for the treatment of TRPC5 receptor mediated disorders or conditions. R1, R2, R3 R4 and R5 have meanings given in the description.
    Type: Grant
    Filed: August 10, 2015
    Date of Patent: September 13, 2016
    Assignee: Hydra Biosciences, Inc.
    Inventors: Bertrand L. Chenard, Randall J. Gallaschun
  • Patent number: 9440972
    Abstract: This invention relates to novel Pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione derivatives of Formula (I): and their use as TRPC5 modulators, pharmaceutical compositions containing the same, and methods of using the same as agents for the treatment of TRPC5 receptor mediated disorders or conditions. R1, R2, R3 and R4 have meanings given in the description.
    Type: Grant
    Filed: August 10, 2015
    Date of Patent: September 13, 2016
    Assignee: Hydra Biosciences, Inc.
    Inventors: Bertrand L. Chenard, Randall J. Gallaschun
  • Patent number: 9359359
    Abstract: Compounds, compositions and methods are described for inhibiting the TRPC5 ion channel and disorders related to TRPC5.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: June 7, 2016
    Assignee: HYDRA BIOSCIENCES, INC.
    Inventors: Bertrand L. Chenard, Randall J. Gallaschun
  • Patent number: 9260431
    Abstract: Compounds and compositions for treating injuries caused by exposure to chemical warfare agents are described herein.
    Type: Grant
    Filed: March 5, 2014
    Date of Patent: February 16, 2016
    Assignee: HYDRA BIOSCIENCES, INC.
    Inventor: Jayhong A. Chong